Rituximab is effective for all four clinical profiles of immunoglobulin G4-related disease (IgG4-RD), but two IgG4-RD profiles, or phenotypes, may show poorer responses, according to a multicenter study in Europe. “Patients in the retroperitoneal and aortic and head and neck-limited phenotypes may be less responsive,” the researchers said, and…
Zenas Biopharma has secured up to $300 million from Royalty Pharma to accelerate the development of obexelimab, its investigational treatment that could provide much-needed relief for people with immunoglobulin G4-related disease (IgG4-RD). In exchange, Royalty Pharma will receive a share of royalties on sales of obexelimab, which is…
Zenas Biopharma said it expects top-line results from INDIGO, a Phase 3 clinical trial testing obexelimab in people with immunoglobulin G4-related disease (IgG4-RD), “around year-end.” We are very pleased with the rapid advancement of our broad obexelimab development program,” Lonnie Moulder, founder and CEO of Zenas, said…
Immunoglobulin G4-related disease (IgG4-RD) affecting the organs and tubes involved in storing and transporting the digestive fluid bile can be challenging to identify, but an early diagnosis — as well as prompt treatment — is “critical” to ensure optimal clinical outcomes. That’s according to the researchers behind a new…
Imaging of the salivary glands can help distinguish IgG4-related disease (IgG4-RD) from other disorders that can cause inflammation in those glands, a new study shows. The findings indicate people with salivary gland inflammation related to IgG4-RD tend to show distinctive patterns of damage to some of the tubes, or…
Eye problems, inflammation in the brain’s pituitary gland, and thickening of the membranes around the brain and spinal cord are the most common neurological complications seen with immunoglobulin G4-related disease (IgG4-RD), a review study reports. Neurological problems in IgG4-RD can usually be managed with standard treatments, though researchers emphasized…
High levels of IgG4 antibodies are not associated with an increased risk of clinical disease activity in people with IgG4-related disease (IgG4-RD) who don’t have active IgG4-RD symptoms, but a sudden rise in these antibodies may predict the recurrence of symptoms, a study found. Monitoring for rising IgG4…
A specific subset of immune cells known as gamma-delta 2 T-cells plays a key role in the development of immunoglobulin G4-related disease (IgG4-RD), a study reports. Particularly, these cells were found to acquire an immune profile, called T helper 2 (Th2)-like phenotype, to strongly promote the formation of plasma…
More than 50,000 people in the U.S. were living with IgG4-related disease (IgG4-RD) as of 2024, a new report on statistics related to the rare immune disease shows. The report provides IgG4-RD epidemiology data, such as the disease’s occurrence, distribution, and patterns, in the U.S. as well as in…
Get regular updates to your inbox.
